Beijing Hotgen Biotech Co. Ltd.

Founded in June 2005, Beijing Hotgen Biotech Co. Ltd. (abbreviated Hotgen Biotech, stock code: 688068) is a high-tech enterprise focusing on the R&D, manufacturing and sales of in vitro diagnostics (IVD) medical and public safety inspection products in the field of biomedicine, and was admitted to the China Sci-Tech Innovation Board (STAR Market) in September 2019.

After several years of research and development, Hotgen Biotech has developed a development platform for bioactive reagents for in vitro diagnostics, an R&D technology platform for the detection of abnormal proteins in sugar chains (sugar capture), an R&D technology platform for magnetic particle chemiluminescence, an R&D technology platform for up-converting phosphorus, The eight main technology platforms, such as the precipitation R&D platform, the Enzyme immunoassay R&D technology platform, molecular diagnostics R&D platform, and instrument R&D technology platform, form a closed system for in vitro diagnostic R&D and production. Hotgen Biotech has built a complete immunodiagnostic technology platform, ranging from high-precision up-converting phosphorus POCT (UPT series), small, medium and large single-cartridge chemiluminescence platforms (MQ60 series) to large-scale fully automated chemiluminescence platform (C2000), enabling the application of the immunodiagnostic platform in the field of complete diagnostic scenarios. The supporting products are widely used in the clinical field and public safety field. Specific users include hospitals at all levels, community health centers, third-party testing centers, and medical facilities, as well as medical and healthcare facilities, disease control centers, public safety, fire safety, military, ports, food, and medicine. surveillance, food and feed companies and other areas of public safety.

Hotgen Biotech has won the second prize of the National Technology Invention Award, the Gold Medal for Independent Innovation, and the second prize of the Chinese Medical Science and Technology Award; In 2018, Hotgen Biotech was awarded the second prize of the "Technical Invention Category of China Rare Earth Science and Technology Award" by the China Rare Earth Society; Top 100 Private Scientific and Technological Innovations and Top 100 Medical Enterprises of the Future; and "Postdoctoral Scientific Research Workstation"; major science and technology projects in the 12th and 13th Five-Year Plan, 863 science and technology projects of the Beijing Science and Technology Commission and Zhongguancun High Precision project is an important project to transform and industrialize technological excellence.

Since its foundation, the company has continuously expanded its business and has now grown into a corporation. At present, Hotgen (Langfang), Hotgen (Jilin), Weikekang Technology, Shunjing Biological and many other subsidiaries have been established. The marketing and service networkHotgen Biotech's technology covers all regions of the country. Each province is equipped with professional technical service engineers, academic engineers, etc., who are responsible for the pre-sales and post-sales work to meet customers' needs. The company has set itself the goal of "the development of biotechnology and the promotion of human health", "quality decides the life and death of the company, customers determine success and failure, talents determine the rise and fall of the company, innovation determines the future of the company", and "tests because I am advanced" as philosophy, high ambitions, technological entrepreneurship and industrial prosperity!